EPO published patent application EP3817742A1 for Temmune Therapeutics NV, covering heterocyclic sulfonamide derivative compounds and their pharmaceutical uses. The patent lists nine inventors (Rogers, Kirby, Shomi, Matsuo, Kobayashi, Kanazawa, Yamaoka, Torizuka, Suzawa) and covers multiple therapeutic categories including cardiovascular (A61P 9/00), neurological (A61P 25/00), anti-inflammatory (A61P 29/00), and immunological (A61P 37/00) applications. Designated states include all major European jurisdictions (DE, FR, GB, IT, ES, NL, etc.).

Pharmaceutical companies developing sulfonamide-based therapeutics should review this patent for potential freedom-to-operate concerns. Generic drug manufacturers or biosimilar developers must assess whether their compounds fall within the scope of these claims. No immediate compliance deadlines apply, but IP clearance searches are advisable for relevant drug development programs.